TRACY DONAHUE: Open Payments
NPI 1093718173 · NOBLESVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,212 in 55 payments from 16 companies in 2025. Trend: 2023 $1,234 · 2024 $1,483 · 2025 $1,212
Food & beverage: $1,212
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $336 |
| GlaxoSmithKline, LLC. | 11 | $177 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $155 |
| Octapharma USA, Inc. | 4 | $114 |
| Grifols USA, LLC | 3 | $71 |
| Azurity Pharmaceuticals, Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| GENZYME CORPORATION | 2 | $52 |
| Amgen Inc. | 3 | $45 |
| Novartis Pharmaceuticals Corporation | 2 | $38 |
Products named: TEZSPIRE, NEFFY, NUCALA, AIRSUPRA, TRELEGY ELLIPTA, Xembify, CUTAQUIG, FASENRA.
Industry payments across IN — which companies pay providers there.
